Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Helicobacter Pylori | Review article

The impact of Helicobacter pylori infection on gut microbiota-endocrine system axis; modulation of metabolic hormone levels and energy homeostasis

Authors: Samaneh Ostad Mohammadi, Abbas Yadegar, Mohammad Kargar, Hamed Mirjalali, Farshid Kafilzadeh

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

The gut microbiota is a complex ecosystem that is involved in the development and preservation of the immune system, energy homeostasis and nutritional status of the host. The crosstalk between gut microbiota and the host cells modulates host physiology and metabolism through different mechanisms. Helicobacter pylori (H. pylori) is known to reside in the gastric mucosa, induce inflammation, and alter both gastric and intestinal microbiota resulting in a broad spectrum of diseases, in particular metabolic syndrome-related disorders. Infection with H. pylori have been shown to affect production level and physiological regulation of the gut metabolic hormones such as ghrelin and leptin which are involved in food intake, energy expenditure and body mass. In this study, we reviewed and discussed data from the literature and follow-up investigations that links H. pylori infection to alterations of the gut microbiota and metabolic hormone levels, which can exert broad influences on host metabolism, energy homeostasis, behavior, appetite, growth, reproduction and immunity. Also, we discussed the strong potential of fecal microbiota transplantation (FMT) as an innovative and promising investigational treatment option for homeostasis of metabolic hormone levels to overcome H. pylori-associated metabolic syndrome-related disorders.
Literature
1.
Scarpellini E, Ianiro G, Attili F, Bassanelli C, de Santis A, Gasbarrini A. The human gut microbiota and virome: potential therapeutic implications. Dig Liver Dis. 2015;47(12):1007–12.PubMedPubMedCentral
2.
Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716–25.PubMed
3.
4.
Baquero F, Nombela C. The microbiome as a human organ. Clin Microbiol Infect. 2012;18(Suppl 4):2–4.PubMed
5.
6.
Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–32.PubMed
7.
Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017;74(16):2959–77.PubMed
8.
Wan SZ, Liu C, Huang CK, Luo FY, Zhu X. Ursolic acid improves intestinal damage and bacterial Dysbiosis in liver fibrosis mice. Front Pharmacol. 2019;10:1321.PubMedPubMedCentral
9.
Tito RY, Chaffron S, Caenepeel C, Lima-Mendez G, Wang J, Vieira-Silva S, et al. Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota. Gut. 2019;68(7):1180–9.PubMed
10.
Naude PJW, et al. Association of maternal prenatal psychological stressors and distress with maternal and early infant faecal bacterial profile. Acta Neuropsychiatr. 2019:1–31.
11.
Browne PD, Aparicio M, Alba C, Hechler C, Beijers R, Rodríguez JM, et al. Human Milk microbiome and maternal postnatal psychosocial distress. Front Microbiol. 2019;10:2333.PubMedPubMedCentral
12.
Moran-Ramos S, et al. Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study. Gut Microbes. 2020:1–18.
13.
Chen X, Sun H, Jiang F, Shen Y, Li X, Hu X, et al. Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing. PeerJ. 2020;8:e8317.PubMedPubMedCentral
14.
Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13.PubMedPubMedCentral
15.
Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Curr Opin Pharmacol. 2019;49:1–5.PubMed
16.
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano G, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.PubMedCentral
17.
Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59(12):1635–42.PubMed
18.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.PubMed
19.
20.
Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev. 2017;279(1):70–89.PubMedPubMedCentral
21.
Geuking MB, Köller Y, Rupp S, McCoy KD. The interplay between the gut microbiota and the immune system. Gut Microbes. 2014;5(3):411–8.PubMedPubMedCentral
22.
Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, et al. High prevalence of antibiotic resistance in Iranian helicobacter pylori isolates: importance of functional and mutational analysis of resistance genes and virulence genotyping. J Clin Med. 2019;8(11):2004.PubMedCentral
23.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.PubMed
24.
Yadegar A, Mohabati Mobarez A, Zali MR. Genetic diversity and amino acid sequence polymorphism in helicobacter pylori CagL hypervariable motif and its association with virulence markers and gastroduodenal diseases. Cancer Med. 2019;8(4):1619–32.PubMedPubMedCentral
25.
Farzi N, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among helicobacter pylori isolates from Iranian patients with different gastric diseases. Infect Genet Evol. 2018;60:26–34.PubMed
26.
Kountouras J, Polyzos SA, Doulberis M, Zeglinas C, Artemaki F, Vardaka E, et al. Potential impact of helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism. 2018;87:18–24.PubMed
27.
Mokhtare M, Mirfakhraee H, Arshad M, Samadani Fard SH, Bahardoust M, Movahed A, et al. The effects of helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia. Diabetes Metab Syndr. 2017;11(Suppl 2):S1031–s1035.PubMed
28.
Yu Y, et al. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females. Exp Ther Med. 2019;17(6):4403–8.PubMedPubMedCentral
29.
Xu X, Li W, Qin L, Yang W, Yu G, Wei Q. Relationship between helicobacter pylori infection and obesity in Chinese adults: a systematic review with meta-analysis. PLoS One. 2019;14(9):e0221076.PubMedPubMedCentral
30.
Xu MY, et al. Nonalcoholic fatty liver disease is associated with helicobacter pylori infection in north urban Chinese: a retrospective study. Gastroenterol Res Pract. 2020;2020:9797841.PubMedPubMedCentral
31.
Yap TW-C, Gan HM, Lee YP, Leow AHR, Azmi AN, Francois F, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PLoS One. 2016;11(3):e0151893.PubMedPubMedCentral
32.
Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265–75.PubMed
33.
Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1288–95.PubMed
34.
Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39(4):509–21.PubMed
35.
Schmidt EKA, Torres-Espin A, Raposo PJF, Madsen KL, Kigerl KA, Popovich PG, et al. Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats. PLoS One. 2020;15(1):e0226128.PubMedPubMedCentral
36.
Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory <em>Clostridium difficile</em> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;67(11):1920.PubMed
37.
Azimirad M, Yadegar A, Asadzadeh Aghdaei H, Kelly CR. Enterotoxigenic Clostridium perfringens infection as an adverse event after Faecal microbiota transplantation in two patients with ulcerative colitis and recurrent Clostridium difficile infection: a neglected agent in donor screening. J Crohns Colitis. 2019;13(7):960–1.PubMed
38.
Vrieze A, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.e7.PubMed
39.
40.
Ridlon JM, Ikegawa S, Alves JMP, Zhou B, Kobayashi A, Iida T, et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res. 2013;54(9):2437–49.PubMedPubMedCentral
41.
Rizzetto L, Fava F, Tuohy KM, Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun. 2018;92:12–34.PubMed
42.
Zhuang M, Shang W, Ma Q, Strappe P, Zhou Z. Abundance of probiotics and butyrate-production microbiome manages constipation via short-chain fatty acids production and hormones secretion. Mol Nutr Food Res. 2019;63(23):1801187.
43.
Grasset E, Burcelin R. The gut microbiota to the brain axis in the metabolic control. Rev Endocr Metab Disord. 2019;20(4):427–38.PubMedPubMedCentral
44.
Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012;3(4):289–306.PubMedPubMedCentral
45.
Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A. 2006;103(26):10011–6.PubMedPubMedCentral
46.
Rodriguez-Castano GP, et al. Bacteroides thetaiotaomicron starch utilization promotes Quercetin degradation and butyrate production by Eubacterium ramulus. Front Microbiol. 2019;10:1145.PubMedPubMedCentral
47.
Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291(5505):881–4.PubMed
48.
Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2017;101(1):47–64.PubMed
49.
Joyce SA, Gahan CG. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis. 2017;35(3):169–77.PubMed
50.
51.
Queipo-Ortuno MI, et al. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One. 2013;8(5):e65465.PubMedPubMedCentral
52.
Wroblewski LE, Peek RM. Helicobacter pylori, Cancer, and the gastric microbiota. Adv Exp Med Biol. 2016;908:393–408.PubMed
53.
Sheh A, Fox JG. The role of the gastrointestinal microbiome in helicobacter pylori pathogenesis. Gut Microbes. 2013;4(6):505–31.PubMedPubMedCentral
54.
Pero R, et al. A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins. Biomolecules. 2019;9(6).
55.
Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):39–45.PubMed
56.
Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, et al. Omeprazole, helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology. 2000;119(2):339–47.PubMed
57.
Wang L, Zhou J, Xin Y, Geng C, Tian Z, Yu X, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28(3):261–6.PubMedPubMedCentral
58.
Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226–36.PubMed
59.
Yang I, Woltemate S, Piazuelo MB, Bravo LE, Yepez MC, Romero-Gallo J, et al. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci Rep. 2016;6:18594.PubMedPubMedCentral
60.
Park CH, Lee AR, Lee YR, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24(1):e12547.PubMed
61.
Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, et al. Association between gut microbiota and helicobacter pylori-related gastric lesions in a high-risk population of gastric Cancer. Front Cell Infect Microbiol. 2018;8:202.PubMedPubMedCentral
62.
Dash NR, Khoder G, Nada AM, al Bataineh MT. Exploring the impact of helicobacter pylori on gut microbiome composition. PLoS One. 2019;14(6):e0218274.PubMedPubMedCentral
63.
Khosravi Y, et al. Proteomics analysis revealed that crosstalk between helicobacter pylori and Streptococcus mitis may enhance bacterial survival and reduces carcinogenesis. Front Microbiol. 2016;7:1462.PubMedPubMedCentral
64.
Kienesberger S, Cox LM, Livanos A, Zhang XS, Chung J, Perez-Perez GI, et al. Gastric helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep. 2016;14(6):1395–407.PubMedPubMedCentral
65.
Yin YN, Wang CL, Liu XW, Cui Y, Xie N, Yu QF, et al. Gastric and duodenum microflora analysis after long-term helicobacter pylori infection in Mongolian gerbils. Helicobacter. 2011;16(5):389–97.PubMed
66.
Navabi N, Johansson MEV, Raghavan S, Lindén SK. Helicobacter pylori infection impairs the mucin production rate and turnover in the murine gastric mucosa. Infect Immun. 2013;81(3):829–37.PubMedPubMedCentral
67.
Espinoza JL, Matsumoto A, Tanaka H, Matsumura I. Gastric microbiota: an emerging player in helicobacter pylori-induced gastric malignancies. Cancer Lett. 2018;414:147–52.PubMed
68.
Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther. 1996;10(1):105–9.PubMed
69.
Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of helicobacter pylori urease and catalase at low pH. Gut. 1997;40(1):25–30.PubMedPubMedCentral
70.
Ziebarth D, Spiegelhalder B, Bartsch H. N-nitrosation of medicinal drugs catalysed by bacteria from human saliva and gastro-intestinal tract, including helicobacter pylori. Carcinogenesis. 1997;18(2):383–9.PubMed
71.
Dong Q, Xin Y, Wang L, Meng X, Yu X, Lu L, et al. Characterization of gastric microbiota in twins. Curr Microbiol. 2017;74(2):224–9.PubMed
72.
Noto JM, Peek RM Jr. The gastric microbiome, its interaction with helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017;13(10):e1006573.PubMedPubMedCentral
73.
Pucci, A. and R.L. Batterham, Endocrinology of the Gut and the Regulation of Body Weight and Metabolism, in Endotext, K.R. Feingold, et al., Editors. 2000, MDText.​com, Inc.: South Dartmouth (MA).
74.
Waldum HL, Rehfeld JF. Gastric cancer and gastrin: on the interaction of helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia. Scand J Gastroenterol. 2019;54(9):1118–23.PubMed
75.
Acbay O, Celik AF, Gundogdu S. Does helicobacter pylori-induced gastritis enhance food-stimulated insulin release? Dig Dis Sci. 1996;41(7):1327–31.PubMed
76.
He C, Yang Z, Cheng D, Xie C, Zhu Y, Ge Z, et al. Helicobacter pylori infection aggravates diet-induced insulin resistance in association with gut microbiota of mice. EBioMedicine. 2016;12:247–54.PubMedPubMedCentral
77.
Allam AS, Bawady S, Abdel-Moaty AS, el-Nakeep S. Effect of helicobacter pylori on insulin resistance in nonobese, nondiabetic, and normolipidemic Egyptian patients. Egypt Liver J. 2018;8(1):23–8.
78.
Vafaeimanesh J, et al. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. SciWorldJ. 2014;2014:391250.
79.
Yeung, A.Y. and P. Tadi, Physiology, Obesity Neurohormonal Appetite And Satiety Control, in StatPearls. 2020, StatPearls Publishing StatPearls Publishing LLC.: Treasure Island (FL).
80.
de Candia P, Matarese G. Leptin and ghrelin: Sewing metabolism onto neurodegeneration. Neuropharmacology. 2018;136(Pt B):307–16.PubMed
81.
Khosravi Y, Bunte RM, Chiow KH, Tan TL, Wong WY, Poh QH, et al. Helicobacter pylori and gut microbiota modulate energy homeostasis prior to inducing histopathological changes in mice. Gut Microbes. 2016;7(1):48–53.PubMedPubMedCentral
82.
Francois F, et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 2011;11:37.PubMedPubMedCentral
83.
Khosravi Y, Seow SW, Amoyo AA, Chiow KH, Tan TL, Wong WY, et al. Helicobacter pylori infection can affect energy modulating hormones and body weight in germ free mice. Sci Rep. 2015;5:8731.PubMedPubMedCentral
84.
Tatsuguchi A, Miyake K, Gudis K, Futagami S, Tsukui T, Wada K, et al. Effect of helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol. 2004;99(11):2121–7.PubMed
85.
Isomoto H, Nakazato M, Ueno H, Date Y, Nishi Y, Mukae H, et al. Low plasma ghrelin levels in patients with helicobacter pylori-associated gastritis. Am J Med. 2004;117(6):429–32.PubMed
86.
Yap TW, et al. Changes in metabolic hormones in Malaysian young adults following helicobacter pylori eradication. PLoS One. 2015;10(8):e0135771.PubMedPubMedCentral
87.
Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66(12):1824–9.PubMed
Metadata
Title
The impact of Helicobacter pylori infection on gut microbiota-endocrine system axis; modulation of metabolic hormone levels and energy homeostasis
Authors
Samaneh Ostad Mohammadi
Abbas Yadegar
Mohammad Kargar
Hamed Mirjalali
Farshid Kafilzadeh
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00608-y

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue

Research article

Association of nutrient patterns and metabolic syndrome and its components in adults living in Tehran, Iran

Research article

Evaluation of the anti-inflammatory and antioxidant effects of the microalgae Nannochloropsis gaditana in streptozotocin-induced diabetic rats

Review article

Gut microbiota: a perspective of precision medicine in endocrine disorders

Research article

Gene set enrichment analysis of α-amylase and α-glucosidase inhibitors of Cassia glauca

Review article

The effect of propolis on anthropometric indices and lipid profile: a systematic review and meta-analysis of randomized controlled trials

Research article

Drug repurposing using computational methods to identify therapeutic options for COVID-19
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits